Comparative pharmacokinetics of levofloxacin in the saliva and blood plasma of patients with pneumonia

Abstract

BACKGROUND: Levofloxacin concentrations do not always reach desired levels when administered at a standard dose; therefore, measuring levofloxacin levels in the blood plasma or other alternative matrices, such as the saliva, can help clinicians make informed decisions concerning the dosage and mode of administration. Saliva, as an object of research, is of particular interest due to the simplicity and non-invasiveness of sampling for analysis.

AIM: This study aimed to determine the comparative pharmacokinetics of levofloxacin in the blood plasma and saliva of patients with community-acquired pneumonia (CAP) and assess the possibility of using saliva as an alternative sampling matrix in pharmacokinetic studies.

MATERIALS AND METHODS: Levofloxacin concentration in the blood plasma and saliva of patients with CAP and volunteers was determined using high-performance liquid chromatography on an Agilent 1200 liquid chromatography (Agilent, USA) with an ultraviolet detector. Sample preparation of bioassays was performed using protein precipitation. Patients and volunteers took 1 tablet (500 mg dose) of levofloxacin per os in the morning, on an empty stomach. Blood and saliva samples were taken at the initial blood sample and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h after taking the drug. The pharmacokinetic parameters were determined, namely C_max as the peak concentration of the drug; Т_max as the time-to-peak concentration; AUC_0–t as the area under the pharmacokinetic curve in the range from 0 to the last experimental point on the curve; AUC_0–∞ as the total area under the pharmacokinetic curve from zero to infinity; t_1/2 as half-life period; MRT as mean residence time of the drug in the blood (h); Cl/F as clearance; and Vss/F as the total distribution volume.

RESULTS: The maximum blood plasma and saliva concentration of patients was reached 1 h after taking the drug and amounted to С_max=5.98±2.89 µg/ml and С_max=4.41±3.83 µg/ml, respectively. Additionally, the maximum concentrations in blood plasma and saliva were recorded 1 h after taking the drug as 5.52±3.07 μg/ml and 3.25±0.85 μg/ml, respectively, in healthy volunteers. The correlation coefficient (r) between the mean values of the levofloxacin concentrations in the blood plasma and the saliva of patients with CAP was 0.953 and that of healthy volunteers was 0.977.

DISCUSSION: Pharmacokinetic parameters were calculated based on blood plasma and saliva concentrations. Their comparative analysis revealed almost the same absorption rate from the gastrointestinal tract in patients and healthy volunteers. Correlation-regression analysis revealed a high correlation between the average values of C_max in saliva and plasma both in the patient (r=0.96) and healthy volunteer group (r=0.98).

CONCLUSIONS: With statistically significant differences in the areas under pharmacokinetic curves in blood plasma and saliva, the remaining pharmacokinetic parameters of saliva and blood plasma did not significantly differ between patients with CAP and healthy volunteers. A significant direct correlation was revealed between the mean concentration and pharmacokinetic parameters in saliva and blood plasma in both groups. The study demonstrated the possibility of using saliva as a biomaterial in the study of levofloxacin pharmacokinetics.

Keywords

levofloxacin / quantitation / blood plasma / saliva / pharmacokinetics / correlation

References

[1] Kocherovets VI, Bunyatyan ND, Olefir YV, et al. Criteria for interchangeability of levofloxacin based medicinal products in the Russian Federation. Khimiko-farmatsevticheskii zhurnal. 2016;50(10):41–46. (In Russ).

[2] Кочеровец В.И., Бунятян Н.Д., Олефир Ю.В., и др. Критерии взаимозаменяемости медицинских препаратов левофлоксацина в Российской Федерации // Химико-фармацевтический журнал. 2016. Т. 50, № 10. С. 41–46.

[3] Sinopal'nikov AI. Levofloxacin: role and place in the treatment of infections of the lower respiratorytracts. Klinicheskaya medicina. 2016;94(11):851–860. (In Russ).

[4] Синопальников А.И. Левофлоксацин: роль и место в лечении инфекций нижних дыхательных путей // Клиническая медицина. 2016. Т. 94, № 11. С. 851–860.

[5] Sokova EA, Arkhipov VV, Mazerkina IA, Muslimova OV. Some Aspects of Drug Induced Nephrotoxicity Assessment. Safety and Risk of Pharmacotherapy. 2020;8(3):123–133. (In Russ). doi: 10.30895/2312-7821-2020-8-3-123-133

[6] Сокова Е.А., Архипов В.В., Мазеркина И.А., Муслимова О.В. Некоторые аспекты оценки лекарственного поражения почек // Безопасность и риск фармакотерапии. 2020. Т. 8, № 3. С. 123–133. doi: 10.30895/2312-7821-2020-8-3-123-133

[7] Mazerkina IA, Evteev VA, Prokofiev AB, et al. β-Lactam Antibio tics – Drug-Drug Interaction Mediated by Organic Anion Transpor ters OAT1 and OAT3. The Bulletin of the Scientific Centre for Expert Evalua tion of Medicinal Products. 2020;10(3):177–183. (In Russ). doi: 10.30895/1991-2919-2020-10-3-177-183

[8] Мазеркина И.А., Евтеев В.А., Прокофьев А.Б., и др. β-лактамные антибиотики – межлекарственное взаимодействие на уровне транспортеров органических анионов ОАТ1 и ОАТ3 // Ведомости Научного центра экспертизы средств медицинского применения. 2020. Т. 10, № 3. С. 177–183. doi: 10.30895/1991-2919-2020-10-3-177-183

[9] Padejskaya EN. Farmakokinetika levofloksatsina kak osnova rezhima dozirovaniya i optimizatsii skhem lecheniya. Pharmacokinetics and Pharmacodynamics. 2005;(2):58–71. (In Russ).

[10] Падейская Е.Н. Фармакокинетика левофлоксацина как основа режима дозирования и оптимизация схем лечения // Фармакокинетика и фармакодинамика. 2005. № 2. С. 58–71.

[11] Krechikov VA. Levofloksatsin pri vnebol'nichnoi pnevmonii: nasto yashchee i perspektivy. Prakticheskaya pul'monologiya. 2016;(1):30–33. (In Russ).

[12] Кречиков В.А. Левофлоксацин при внебольничной пневмонии: настоящее и перспективы // Практическая пульмонология. 2016. № 1. С. 30–33.

[13] Friedman H, Song X, Crespi S, Navaratnam P. Comparative ana lysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health. 2009;12(8):1135–1143. doi: 10.1111/j.1524-4733.2009.00576.x

[14] Friedman H., Song X., Crespi S., Navaratnam P. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia // Value Health. 2009. Vol. 12, N 8. P. 1135–1143. doi: 10.1111/j.1524-4733.2009.00576.x

[15] Cao G, Zhu Y, Xie X, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. Exp Ther Med. 2020;20(1):607–616. doi: 10.3892/etm.2020.8715

[16] Cao G., Zhu Y., Xie X., et al. Pharmacokinetics and pharmaco dynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation // Exp Ther Med. 2020. Vol. 20, N 1. P. 607–616. doi: 10.3892/etm.2020.8715

[17] Cao G, Zhang J, Wu X, et al. Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. J Clin Pharm Ther. 2013;38(5):394–400. doi: 10.1111/jcpt.12074

[18] Cao G., Zhang J., Wu X., et al. Pharmacokinetics and phar ma co dynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization // J Clin Pharm Ther. 2013. Vol. 38, N 5. P. 394–400. doi: 10.1111/jcpt.12074

[19] Zyryanov SK, Kozlov RS, Makushkin BB. A Novel View on Common Antibiotics: How to Properly Use Pharmacodynamic Parameters. Clinical Microbiology and Antimicrobial Chemotherapy. 2016;18(2):125–129.

[20] Зырянов С.К., Козлов Р.С., Макушкин Б.Б. Новый взгляд на известные антибиотики: как правильно использовать фармакодинамические параметры // Клиническая микробиология и антимикробная химиотерапия. 2016. Т. 18, № 2. С. 125–129.

[21] Ghimire S, Maharjan B, Jongedijk EM, et al. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2019;63(5).

[22] Ghimire S., Maharjan B., Jongedijk E.M., et al. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis // Antimicrob Agents Chemother. 2019. Vol. 63, N 5. P. doi: 10.1128/AAC.02379-18

[23] doi: 10.1128/AAC.02379-18

[24] Кочурова Е.В. Диагностические возможности слюны // Клиническая лабораторная диагностика. 2014. Т. 59, № 1. С. 13–15.

[25] Kochurova EV. The diagnostic possibilities of saliva. Russian Clinical Laboratory Diagnostics. 2014;59(1):13–15.

[26] Абаимов Д.А., Сариев А.К., Носкова Т.Ю., и др. Современные технологии в терапевтическом лекарственном мониторинге // Эпилепсия и пароксизмальные состояния. 2013. Т. 5, № 2. С. 31–41.

[27] Abaimov DA, Sariev AK, Noskova TY et al. Modern technologies in therapeutic drug monitoring (review). Epilepsy and paroxysmal conditions. 2013;5(2):31–41.

[28] Madhavi M., Mary Priyanka U. Influence of follicular and luteal phase on levofloxacin рharmacokinetics in female volunteers // Int J Pharm Bio Sci. 2014. Vol. 5, N 1. P. 305–312.

[29] Madhavi M, Mary Priyanka U. Influence of follicular and luteal phase on levofloxacin rharmacokinetics in female volunteers. Int J Pharm Bio Sci. 2014;5(1):305–312.

[30] Стародубцев А.К., Золкина И.В., Кондратенко С.Н., Белякова Г.А. Изучение фармакокинетики пентоксифиллина по динамике его распределения в крови и слюне здоровых добровольцев // Химико-фармацевтическй журнал. 2008. Т. 42, № 1. С. 3–5. doi: 10.30906/0023-1134-2008-42-1-3-5

[31] Starodubcev AK, Zolkina IV, Kondratenko SN, Belyakova GA. Pharmacokinetics of pentoxifylline studied using the dynamics of drug distribution in the blood and saliva of healthy volunteers. Khimikofarmatsevticheskii zhurnal. 2008;42(1):3–5. (In Russ). doi: 10.30906/0023-1134-2008-42-1-3-5

[32] Mohamed S., Mvungi H.C., Sariko M., et al. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania // J Antimicrob Chemother. 2021. Vol. 76, N 6. P. 1547–1552. doi: 10.1093/jac/dkab057

[33] Mohamed S, Mvungi HC, Sariko M, et al. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. J Antimicrob Chemother. 2021;76(6):1547–1552. doi: 10.1093/jac/dkab057

[34] Руководство по экспертизе лекарственных средств. Том 1 / под ред. А.Н. Миронова. Москва: Гриф и К., 2013

[35] Mironov AN. Rukovodstvo po ekspertize lekarstvennykh sredstv. Tom 1. Moscow: Grif i K; 2013.

[36] U.S. Department of Health anmd Haman Services Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. Biopharmaceutics, 2018.

[37] U.S. Department of Health anmd Haman Services Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. Biopharmaceutics; 2018.

RIGHTS & PERMISSIONS

Krasnykh L.M., Goroshko O.A., Tsyganko D.V., Berdnicova N.G., Krasnyanskaya V.G., Checha O.A.